SOFOSBUVIR\VELPATASVIR\VOXILAPREVIR: 1,207 Adverse Event Reports & Safety Profile
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
1,207
Total FAERS Reports
50 (4.1%)
Deaths Reported
109
Hospitalizations
1,207
As Primary/Secondary Suspect
19
Life-Threatening
13
Disabilities
First Report: 2014 · Latest Report: 20250801
What Are the Most Common SOFOSBUVIR\VELPATASVIR\VOXILAPREVIR Side Effects?
#1 Most Reported
Fatigue
204 reports (16.9%)
#2 Most Reported
Headache
140 reports (11.6%)
#3 Most Reported
Treatment failure
133 reports (11.0%)
All SOFOSBUVIR\VELPATASVIR\VOXILAPREVIR Side Effects by Frequency
| Side Effect | Reports | % of Total | Deaths | Hosp. |
|---|---|---|---|---|
| Fatigue | 204 | 16.9% | 0 | 3 |
| Headache | 140 | 11.6% | 0 | 4 |
| Treatment failure | 133 | 11.0% | 2 | 1 |
| Drug ineffective | 119 | 9.9% | 1 | 5 |
| Nausea | 107 | 8.9% | 0 | 8 |
| Hepatitis c | 106 | 8.8% | 3 | 4 |
| Diarrhoea | 87 | 7.2% | 0 | 6 |
| Vomiting | 37 | 3.1% | 0 | 4 |
| Hepatocellular carcinoma | 33 | 2.7% | 5 | 5 |
| Insomnia | 30 | 2.5% | 0 | 0 |
| Drug interaction | 26 | 2.2% | 0 | 2 |
| Death | 25 | 2.1% | 25 | 3 |
| Hepatic cirrhosis | 25 | 2.1% | 1 | 3 |
| Abdominal discomfort | 24 | 2.0% | 0 | 3 |
| Intentional dose omission | 21 | 1.7% | 0 | 2 |
| Product dose omission | 21 | 1.7% | 0 | 1 |
| Asthenia | 19 | 1.6% | 0 | 1 |
| Decreased appetite | 19 | 1.6% | 0 | 1 |
| Genotype drug resistance test positive | 19 | 1.6% | 0 | 1 |
| Off label use | 19 | 1.6% | 1 | 2 |
Who Reports SOFOSBUVIR\VELPATASVIR\VOXILAPREVIR Side Effects? Age & Gender Data
Gender: 29.4% female, 70.6% male. Average age: 58.3 years. Most reports from: US. View detailed demographics →
Is SOFOSBUVIR\VELPATASVIR\VOXILAPREVIR Getting Safer? Reports by Year
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2014 | 5 | 0 | 0 |
| 2016 | 2 | 0 | 0 |
| 2017 | 85 | 2 | 6 |
| 2018 | 277 | 7 | 26 |
| 2019 | 179 | 4 | 14 |
| 2020 | 73 | 3 | 11 |
| 2021 | 35 | 5 | 9 |
| 2022 | 26 | 6 | 7 |
| 2023 | 15 | 0 | 4 |
| 2024 | 7 | 2 | 0 |
| 2025 | 12 | 2 | 0 |
What Is SOFOSBUVIR\VELPATASVIR\VOXILAPREVIR Used For?
| Indication | Reports |
|---|---|
| Chronic hepatitis c | 366 |
| Hepatitis c | 338 |
| Product used for unknown indication | 142 |
| Antiviral treatment | 12 |
| Hepatitis c virus test positive | 10 |
| Hepatic cirrhosis | 8 |
| Hepatitis viral | 6 |
| Hepatitis b | 5 |
SOFOSBUVIR\VELPATASVIR\VOXILAPREVIR vs Alternatives: Which Is Safer?
SOFOSBUVIR\VELPATASVIR\VOXILAPREVIR vs SOLIFENACIN
SOFOSBUVIR\VELPATASVIR\VOXILAPREVIR vs SOLIRIS
SOFOSBUVIR\VELPATASVIR\VOXILAPREVIR vs SOLOSTAR
SOFOSBUVIR\VELPATASVIR\VOXILAPREVIR vs SOLRIAMFETOL
SOFOSBUVIR\VELPATASVIR\VOXILAPREVIR vs SOLU-MEDROL
SOFOSBUVIR\VELPATASVIR\VOXILAPREVIR vs SOMATREM
SOFOSBUVIR\VELPATASVIR\VOXILAPREVIR vs SOMATROPIN
SOFOSBUVIR\VELPATASVIR\VOXILAPREVIR vs SONIDEGIB
SOFOSBUVIR\VELPATASVIR\VOXILAPREVIR vs SORAFENIB
SOFOSBUVIR\VELPATASVIR\VOXILAPREVIR vs SORGHUM HALEPENSE POLLEN
Official FDA Label for SOFOSBUVIR\VELPATASVIR\VOXILAPREVIR
Official prescribing information from the FDA-approved drug label.